Low Level laser Therapy (LLLT) Cold Laser - THOR Laser

Do More With A THOR
French Version

LLLT reduces oral mucositis

Low Level Laser Therapy:

  • Reduces the development of oral mucositis.
  • Reduces pain, severity and duration of oral mucositis
  • Treatment time 5-10 mins
  • No side effects

EVIDENCE-BASED APPLICATIONS

  • oral mucositis
  • Lymphoedema
  • BRONJ

EMERGING APPLICATIONS

  • Trismus
  • Xerostomia
  • Dermatitis
  • Fibrosis
  • Pain control

OTHER POTENTIAL APPLICATIONS TO BE STUDIED

  • Dysphagia
  • Taste
  • Hearing loss
  • Osteoradionecrosis
  • Voice changes

Clinical Trial Conclusions

"Our results have indicated that the use of low power laser in HSCT patients is a powerful instrument in the treatment of overt OM and is now a standard procedure in this group of patients in our hospital."

Clinical Trial authors Antunes HS, Ferreira EM, de Matos VD, Pinheiro CT, Ferreira CG

"The ease of use of LLLT, high patient acceptance, and the positive results achieved, make this therapy feasible for the prevention and treatment of OM in young patients."

Clinical Trial authors Abramoff MM, Lopes NN, Lopes LA, Dib LL, Guilherme A, Caran EM, Barreto AD, Lee ML, Petrilli AS

"There is consistent evidence from small high-quality studies that red and infrared LLLT can partly prevent development of cancer therapy-induced OM. LLLT also signi´Čücantly reduced pain, severity and duration of symptoms in patients with cancer therapy-induced OM."

Clinical Trial authors Bjordal JM, Bensadoun RJ, Tuner J, Frigo L, Gjerde K, Lopes-Martins RA

"Our results indicate that the use of upfront low power laser in patients who have undergone HSCT is a powerful instrument in reducing the incidence of OM and is now standard in our center."

Clinical Trial authors Antunes HS, de Azevedo AM, da Silva Bouzas LF, Adao CA, Pinheiro CT, Mayhe R, Pinheiro LH, Azevedo R, D'Aiuto de Matos V, Rodrigues PC, Small IA, Zangaro RA, Ferreira CG

"Laser therapy was effective in preventing and treating oral effects induced by radiotherapy and chemotherapy, thus improving the patient's quality of life."

Clinical Trial authors Zanin T, Zanin F, Carvalhosa AA, de Souza Castro PH, Pacheco MT, Zanin IC, Junior AB

Are you a patient? Pass this document on to your Oncologist

Download our white paper on LLLT and oral mucostitis Includes 34 clinical trial abstracts

What is LLLT ?

Low Level Laser Therapy is the application of light of damaged tissues to improve the speed and quality of healing. It works by increasing cellular energy (ATP) and reducing free radicals (oxidative stress). There are over 300 RCTs published on LLLT for a wide range of painful and non healing applications including 14 controlled clinical trials on oral mucositis.

How LLLT works

One of the main effects of LLLT is on mitochondrial function: There are hundreds of different cell types in the body, each performing different functions, they all contain lots of mitochondria, (cellular power plants) which generate most of the cell's supply of energy (ATP). Mitochondria are also involved in a range of other cellular processes, including signalling, differentiation, inflammation, cell survival, cell death and are consequently implicated in many diseases.

Mitochondria in stressed or ischaemic tissues produce nitric oxide (NOmt) which binds to cytochrome c oxidase, competitively displacing oxygen. This causes increased oxidative stress and reduced ATP, leading to inflammation and poor cellular function.

Light of the correct wavelength (generated by low intensity lasers and LED's), when applied to stressed tissues, is absorbed by cytochrome c oxidase. The light displaces the NOmt thereby reducing oxidative stress and increasing ATP production; this reduces inflammation and increases cell metabolism.

The subsequent cascade of downstream metabolic effects have been shown to include increased exchange of Ca2+, secretion of growth factors, activation of enzymes & other secondary messengers.

Within hours and sometimes minutes following LLLT, increases in cellular activity have been shown in vitro and in vivo in neutrophils, macrophages, fibroblasts, mast cells, endothelial cells and keratinocytes. Reduced inflammatory markers including prostaglandin E2, interleukin 1ß and TNF a have also been seen in many studies.

Clinical trials show a significant improvement in healing of wounds and reduction of pain. A recent systematic review on LLLT for OM found that it reduces pain, severity and duration of chemotherapy and radiotherapy induced oral mucositis.

The Multinational Association for Support in Cancer care now recommend LLLT for the prevention of oral mucositis in adult patients receiving hematopoietic stem cell transplantation conditioned with high-dose chemotherapy. A new suggestion was made for low-level laser for the prevention of oral mucositis in patients undergoing radiotherapy, without concomitant chemotherapy, for head and neck cancer.

Prices from $7,000 to $23,000 (£4,000 - £14,000)

THOR LX2 Dental Package for a range of oral pathologies, orthodontic procedures and orofacial pain syndromes.

CLICK HERE to contact sales Training course information

Low Level Laser Therapy LLLT oral mucositis

Product information and purchase enquiry

Sorry for the long form.

We are a global company and our computer needs to know who to direct your enquiry to.

* Mandatory field - this automatically directs your enquiry to the correct department


Receive the LLLT Monthly Research News

See previous edition. Please add me to the monthly THOR training, research and conference Newsletter.



OUR CUSTOMERS INCLUDE:
Our customers include: Harvard Medical School, Massachusetts General Hospital, British Army, RAF, Royal Navy, Team GB, Manchester United, MIT, Harvard School of Public Health, Cedars Sinai, City of Hope, USUHS
THOR Customers

POSITIVE SYSTEMATIC REVIEWS PUBLISHED BY:

The British Medical Journal (BMJ), The Lancet, the International Association for the Study of Pain (IASP), the World Health Organisation (WHO), the Multinational Association for Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO)

REGULATORY APPROVALS INCLUDE:

Regulatory approvals include FDA, European CE mark, TGA Australia, Health Canada